(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/081928 A1

(51) International Patent Classification:
A61K 31/403 (2006.01) *C07D 401/04* (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:
PCT/US2021/055105

(22) International Filing Date:
14 October 2021 (14.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/091,897 14 October 2020 (14.10.2020) US

(71) Applicant: **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(72) Inventors: **NASVESCHUK, Christopher, G.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **ANDERSON, Corey, Don**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **HENDERSON, James, A.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **GARZA, Victoria**; 10614 Burr Oak Drive, San Antonio, TX 78230 (US). **LIANG, Yanke**; c/o C4 Therapeutics, Inc., 490 Aresenal Way, Suite 200, Watertown, MA 02472 (US). **MOUSTAKIM, Moses**; 240 NW 25th Street, Apt. 822, Miami, FL 33127 (US). **JACKSON, Katrina, L.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **DUPLESSIS, Martin**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(74) Agent: **BELLOWS, Brent, R.** et al.; Knowles Intellectual Property Strategies LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS

FIG. 71



(57) Abstract: Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.

WO 2022/081928 A1